External views of the Fizer Headquarters Building in New York City on 29 January 2023.
See press | Corbis News | Getty images
Fizer On Tuesday, the cost reduction and its full year’s adjusted profit guidance on its strong commercial performance this year increased.
The company also reported the results of the second quarter, which is at the top of the estimates of Wall Street for the period, as its Kovid products jumped from revenue and some other drugs.
Fizer shares increased by more than 2% in premarket trading on Tuesday.
Physicians are now expected to have a full year’s adjusted profit between $ 2.90 and $ 3.10, with previous guidance from $ 2.80 to $ 3 per share. The company maintained its 2025 revenue forecast from $ 61 billion to $ 64 billion.
“We extended our adjusted diluted EPS guidance throughout our whole year, showing confidence in our ability to execute against strategic priorities and give strong results for shareholders,” Fizer CFO David Denton said in a release.
The entire year’s approach includes a fee of $ 1.35 billion or 20 cents per share related to the company’s licensing deal with a Chinese drug manufacturer to develop and sell its cancer treatment outside China. The allegation will be registered in the third quarter, the Fizer said.
Results also struggle with Physics and other drug manufacturers Donald Trump‘S Call to reduce drug prices Brace for America and for him Tariff employed on pharmaceuticals Imported into the country.
Eat for the attitude of Fizer Trump is currently installed Tariff Changes in the price of potential drug on China, Canada and Mexico, as well as this year President’s letter Last week, the Fizzer was calling to take steps to reduce the drug prices by 29 September. In May, the letter came after Trump that a controversial plan signed an executive order to revive the “most preferred nation” policy, which aims Slash drug cost To reduce the prices of some drugs in the US significantly abroad.
The release of Fizer on Tuesday did not provide specific costs for those factors. In April, Physic officials said that at that time the company’s 2025 guidance included $ 150 million in the cost expected from Trump’s existing tariff, but not sector-specific levies.
Here the company told what the Wall Street was expecting for the second quarter, based on a survey of analysts by LSEG:
- earnings per share: 78 cents adjusted vs 58 cents expected
- Income: $ 14.65 billion vs $ 13.56 billion is expected
For the second quarter, Fizer booked a net income of $ 2.91 billion, or 51 cents per share. It compares with a net income of $ 41 million, or 1 percent per share during the same period a year ago.
The company recorded an income of 78 cents per share for the quarter, except for some items, which involves reorganization of abstract property.
Fizer recorded a revenue of $ 14.65 billion for the second quarter, which was 10% from the same period a year ago.
Results come after Fizer in April Expanded your cost cut effortsThe purpose of which is to help the pharmaceutical giants recover from the rapid decline of its covid business and stock price over the years. With the additional steps announced in April, Phiseer is now expected to distribute around $ 7.7 billion in savings by the end of 2027 from two different cost-cutting programs.
Kovid products, strength from other drugs
The company stated that the increase in sales was mainly operated by high revenue for several products, including fugitive drugs, which are used to treat a certain type of cardiomyopathy, heart muscle disease.
It also includes fizzle’s covid products. The company’s Covid Vaccine, Komirnati booked $ 381 million in revenue for the second quarter. This is 96% from the year-ei-year period due to the high market share of the Fizer in the Covid Shot Market and the more contractual delivery in some international markets.
According to Strikint’s estimates, analysts expected a shot at $ 205.3 million for the quarter.
Fizer’s Antiviral Covid Pil Paxlowid posted $ 427 million in sales for the second quarter. It is 70% above the same period a year ago, mainly due to a high American net value for pill between other factors. The increase in sales was an offset with low covid infections in the US and some global markets and the procurement of Paxloid’s low international government.
Striketing estimates said analysts expected that there would be a sale of $ 259.1 million in sales for this period.
Fizzle bladder cancer drug padsv and blood thinner alicis, which she shared with Bristol Myers Squib, also contributed to the revenue growth. Both estimate for the period of analysts.
The company’s revenue growth was offset by selling less than its breast cancer drug ibrance. Lack of drug was due to the large -scale US net value, which was due to the impact of high manufacturer exemption from the provisions of inflation acts that re -designs the Medicare Part D benefits, as well as generic competition and at the time of shipment in some international markets.
